# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007063
Filing Date
2025-05-09
Accepted
2025-05-09 07:04:04
Documents
55
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | plx-20250331x10q.htm iXBRL | 10-Q | 793770
2 | EX-3.7 | plx-20250331xex3d7.htm | EX-3.7 | 166470
3 | EX-31.1 | plx-20250331xex31d1.htm | EX-31.1 | 12462
4 | EX-31.2 | plx-20250331xex31d2.htm | EX-31.2 | 12631
5 | EX-32 | plx-20250331xex32.htm | EX-32 | 6697
6 | EX-32.2 | plx-20250331xex32d2.htm | EX-32.2 | 6725
7 | GRAPHIC | plx-20250331x10q005.jpg | GRAPHIC | 76005
8 | GRAPHIC | plx-20250331x10q006.jpg | GRAPHIC | 58451
9 | GRAPHIC | plx-20250331x10q007.jpg | GRAPHIC | 52258
10 | GRAPHIC | plx-20250331x10q008.jpg | GRAPHIC | 38391
11 | GRAPHIC | plx-20250331x10q009.jpg | GRAPHIC | 56626
12 | GRAPHIC | plx-20250331x10q010.jpg | GRAPHIC | 40218
| Complete submission text file | 0001558370-25-007063.txt |  | 4424971

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
13 | EX-101.SCH | plx-20250331.xsd | EX-101.SCH | 25542
14 | EX-101.CAL | plx-20250331_cal.xml | EX-101.CAL | 36474
15 | EX-101.DEF | plx-20250331_def.xml | EX-101.DEF | 85607
16 | EX-101.LAB | plx-20250331_lab.xml | EX-101.LAB | 189850
17 | EX-101.PRE | plx-20250331_pre.xml | EX-101.PRE | 156826
58 | EXTRACTED XBRL INSTANCE DOCUMENT | plx-20250331x10q_htm.xml | XML | 376195

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 25928332
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)